HDAC9 and breast carcinoma: SAHA is the first HDAC inhibitor to be approved for cancer therapy by the US Food and Drug Administration (FDA) and has been used alongside capecitabine in phase 1 and phase 2 clinical trials against advanced breast cancer [17].